elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Cabazitaxel
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Cabazitaxel
RIS
0.002
(Research Intensity Score)
Papers
284
Top papers
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
2023 · 209 citations
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2021 · 1126 citations
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2022 · 274 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
2025 · 38 citations
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
2024 · 60 citations
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
2019 · 671 citations
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
2025 · 34 citations
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
2023 · 98 citations
Newest papers
Data from Clonal Hematopoiesis after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
2026 · 1 citations
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
2026 · 2 citations
Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
2026
CO24 REAL-WORLD COMPARATIVE EFFECTIVENESS OF LUTETIUM-177-PSMA-617 VERSUS CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
2026
Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy
2026
Evaluation of [ 225 Ac]Ac‐PSMA‐617 vis‐a‐vis Rechallenge [ 177 Lu]Lu‐PSMA‐617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real‐World Clinical Scenario
2026
Survival Outcomes Based on Line of Therapy and Treatment Trends With Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
2026
Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure.
2026
Browse all papers →
Cabazitaxel's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Cabazitaxel's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link